Is it though? Like that's median over phase 1, phase 2, and phase 3 trials, with a bias towards phase 1 and phase 2 trials. Considering phase 3 trials on average only cost 19 million, that's not too out of reach considering yeah, less regulation means cheaper so I doubt this would be on the upper end of that number, though we will have to see what numbers they put out.
Market Data 
Markets 
AI
